PDF factsheet
      Z

antiplatelets drug in diabetes type 2 for all type of patients, clinical trials results

aspirin versus no treatment
PPP (diabetics sub group), 2003
aspirin 100mg daily
versus
control
men and women with diabetes and without a previous cardiovascular event aged >50 with >=1 risk factors for cardiovascular disease - sub group of diabetic patientsopen
Follow-up duration: 3.6 y
Italy
JPAD, 2008
NCT00110448
low-dose aspirin (81 or 100 mg per day)
versus
no aspirin
patients with type 2 diabetes without a history of atherosclerotic diseaseopen
Follow-up duration: 4.37 y median
Japan
aspirin versus placebo
PHS (diabetics sub group), 1989
aspirin 325 mg every other day
versus
placebo
healthy men (diabetic sub group of patients enrolled if PHS)double blind
Follow-up duration: 5 y
ETDRS, 1992
aspirin 650mg once daily
versus
placebo
patients with diabetes mellitus (Type I or II)double blind
Follow-up duration: 60 months
WHS (diabetics sub group), 2005
aspirin 100mg on alternate days
versus
placebo
healthy women 45 years of age or older - diabetics sub groupsdouble blind
Follow-up duration: 10.1 y
US
POPADAD aspirin, 2008
ISRCTN53295293
aspirin 100mg daily
versus
placebo
patients with diabetes mellitus and asymptomatic peripheral arterial diseasedouble blind
Follow-up duration: nov 1997 - jul 2001
Scotland
DAMAD, 1989
aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily)
versus
placebo
patients with early diabetic retinopathydouble blind
Follow-up duration: 3 y
picotamide versus placebo
Cocozza, 1995
picotamide 300 mg TID
versus
placebo
normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (< 50%) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic eventsdouble blind
Follow-up duration: 24 months
Italy
sulfinyrazone versus placebo
Dutch, 1980
sulfinyrazone
versus

Follow-up duration: 32 months
ticlopidine versus placebo
Birmingham-A, 1979
ticlopidine 100, 250, 500 mg
versus

Follow-up duration: 2 months
London diabetes, 1983
ticlopidine 500mg
versus

Follow-up duration: 12 months
TIMAD, 1984
ticlopidine 500mg
versus

Follow-up duration: 32m
BTRS, 1992
ticlopidine 500mg/d
versus
placebo
insulin-treated diabetics with background retinopathydouble blind
Follow-up duration: 48 months
Nyberg, 1984
ticlopidine 500mg daily
versus
placebo
insulin dependent diabetes complicated by nephropathydouble blind
Follow-up duration: 12 months

  Options


in first

in second

  Filter